AbCellera (ABCL) Misses Q4 EPS by 5c

AbCellera (NASDAQ: ABCL) reported Q4 EPS of ($0.16), $0.05 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $9.2 million versus the consensus estimate of $8.89 million.

For earnings history and earnings-related data on AbCellera (ABCL) click here.

You May Also Be Interested In

• AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
• Immunome, Inc. (IMNM) Reports Q2 Loss of $0.65
• Snail, Inc. (SNAL) Reports Q3 Loss of $0.36